PMID- 33213221
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20220426
IS  - 1744-8379 (Electronic)
IS  - 1473-7167 (Linking)
VI  - 21
IP  - 5
DP  - 2021 Oct
TI  - Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic 
      Jordanians: a Markov modeling of cardiovascular diseases prevention.
PG  - 1069-1079
LID - 10.1080/14737167.2021.1838900 [doi]
AB  - BACKGROUND: Cardiovascular diseases (CVDs) are responsible for one third of 
      global deaths and the main cause of death among Jordanians. Pharmacist-led care 
      was outlined previously as a cost-effective approach in the management of chronic 
      illness; however, this is not well studied in low to middle-income countries. AIM 
      AND OBJECTIVES: To assess the cost-effectiveness of pharmacist-led care versus 
      usual care in preventing CVDs in Type 2 Diabetes Mellitus (T2DM). METHOD: A 
      Markov model of one-year cycle length and 10-year time horizon was constructed to 
      simulate 10-year CVD events, mortality, and costs for two hypothetical cohorts; 
      usual care and pharmacist-led care, respectively, of Jordanian patients suffering 
      from T2DM. Public health provider perspective was adopted. Outcomes examined were 
      incremental costs, LYGs, and incremental cost-effectiveness ratio (ICER). 
      Deterministic and probabilistic sensitivity analysis (PSA) assessed the 
      robustness of the results. RESULT: The pharmacist-led care generated an 
      additional 0.3 LYG/patient at an additional cost of JD1,238.78 (US$1,747.24) 
      comparing to the usual care in the 10-year base-case analysis. Deterministic and 
      PSA supported the robustness of base-case findings, indicating that 
      pharmacist-led care is cost-effective. CONCLUSION: The findings outline long-term 
      clinical and economic benefits of expanding clinical pharmacist's roles in direct 
      patient care services.
FAU - Mousa, Rimal
AU  - Mousa R
AUID- ORCID: 0000-0002-1788-0281
AD  - Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, 
      Amman, Jordan.
FAU - Hammad, Eman
AU  - Hammad E
AD  - Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, 
      Amman, Jordan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201124
PL  - England
TA  - Expert Rev Pharmacoecon Outcomes Res
JT  - Expert review of pharmacoeconomics & outcomes research
JID - 101132257
SB  - IM
MH  - Cardiovascular Diseases/economics/*prevention & control
MH  - Cohort Studies
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/complications/economics/*therapy
MH  - Female
MH  - Humans
MH  - Jordan
MH  - Male
MH  - Markov Chains
MH  - Middle Aged
MH  - Pharmaceutical Services/economics/*organization & administration
MH  - Pharmacists/economics/*organization & administration
MH  - Professional Role
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Jordan
OT  - cardiovascular disease
OT  - collateral damage
OT  - diabetes
OT  - disease management
OT  - middle east
OT  - patient stratification
OT  - pharmacist
OT  - predictive preventive personalized medicine
OT  - prevention
EDAT- 2020/11/21 06:00
MHDA- 2021/10/07 06:00
CRDT- 2020/11/20 05:27
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
PHST- 2020/11/20 05:27 [entrez]
AID - 10.1080/14737167.2021.1838900 [doi]
PST - ppublish
SO  - Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1069-1079. doi: 
      10.1080/14737167.2021.1838900. Epub 2020 Nov 24.